An implantable or injectable scaffold comprising immunostimulatory compounds and a suppressor of regulatory T cell induction is provided for use in immunotherapy treatments, including the treatment of cancers and other tumors, in particular solid tumors including inoperable tumors, as well as for other applications of immune enhancement and/or suppression.

Devices for and related methods of treating a subject having a neurological injury to prevent or mitigate secondary injury are described. In an example, the devices include a base and a plurality of microneedles protruding from the base, the microneedles including a biocompatible and biodegradable matrix, and a neurologically active ingredient disposed within the matrix. In an example, a portion of the plurality of microneedles is shaped to penetrate the dura when the device is placed in contact with the dura.

An oral dissolving film containing nano- or micro-encapsulated bioactive material and methods of forming the film. The film may be prepared by dispensing a mixture of a film-forming agent, a crosslinking agent, a solution of nano- or micro-encapsulated bioactive material, and a photoinitiator into a plurality of wells in a tray using a 3D printer. The dispensed material is exposed to radiation in order to crosslink the material and form a film.

Provided herein is a topical composition comprising tapinarof and methods of treatment of cutaneous adverse effects caused by oncological therapy with the tapinarof composition. The tapinarof compositions of this invention are useful for the treatment, prevention or amelioration of cutaneous and/or mucosal adverse effect caused by oncological therapy selected from chemotherapy, immunotherapy, radiation therapy, targeted therapy, hormone therapy and stem cell transplant therapy.

The present invention relates to a vaginal drug delivery device configured to safely and effectively deliver a therapeutic formulation in the vagina at or near a desired target area for a specified time period.

The present disclosure describes compounds of Formula (I) or a pharmaceutically acceptable salt thereof:

##STR00001##

wherein: R.sup.1 and R.sup.2 are each independently (CH.sub.3(CH.sub.2).sub.m).sub.2CH—, (CH.sub.3(CH.sub.2).sub.m)(CH.sub.3(CH.sub.2).sub.m-1)CH, (CH.sub.3(CH.sub.2).sub.m)(CH.sub.3(CH.sub.2).sub.m-2)CH, (CH.sub.3(CH.sub.2).sub.m).sub.2CHCH.sub.2—, or (CH.sub.3(CH.sub.2).sub.m)(CH.sub.3(CH.sub.2).sub.m-1)CHCH.sub.2—, wherein m is 4-11; L.sup.1 and L.sup.2 are each independently absent, a linear C.sub.1-5 alkylene, or (CH.sub.2).sub.p—O—(CH.sub.2).sub.q, wherein p and q are each independently 1-3; R.sup.3 is a linear C.sub.2-5 alkylene optionally substituted with one or two methyl groups; R.sup.4 and R.sup.5 are each independently H or C.sub.1-6 alkyl; X is O or S; and n is 0-2.

The present invention provides a method for treating a disease or condition in a subject, comprising administering to the subject's skin a composition comprising an effective amount of one or more cannabinoids, wherein the composition is administered with a microneedle delivery device.

This disclosure relates to a method of treating, preventing, or reducing a symptom of a virus infection, including a SARS-CoV-2 infection, by administering an effective amount of tdsRNA optionally with an anti-viral agent, to a subject.

A composition and method for the treatment of Alzheimer's disease and related amyloid plaque development and reduction of amyloid plaque, amyloidosis and amyotrophic lateral sclerosis, includes an effective amount of a compound selected from the group consisting of phytic acid, a phytate salt, an isomer or hydrolysate of phytic acid or a phytate salt, or a mixture of any combination thereof, being administered to a person in an amount from about 0.5 grams to about 18.75 grams per day.

Improved dermal filler formulation comprising a hyaluronic acid and a botulinum toxin.